Compare
Eucrisa vs. Opzelura

Eucrisa (crisaborole) is an ointment that's used to treat eczema for people 3 months and older. The medication is a phosphodiesterase 4 (PDE4) inhibitor that works to help reduce skin inflammation and itching from eczema. The ointment is usually applied to the affected area(s) of skin twice a day. The most common side effect is burning or stinging on the skin where you apply the medication.

• Mild-to-moderate eczema

• Pain, burning, or stinging where the medication is applied (4%)

• Allergic reactions

Opzelura (ruxolitinib) is a topical Janus kinase (JAK) inhibitor. It's a non-steroid cream used to treat atopic dermatitis (eczema) and nonsegmental vitiligo (a condition where skin loses its color) in adults and children ages 12 years and older. Opzelura (ruxolitinib) is applied directly on the skin twice daily. Even though Opzelura (ruxolitinib) has the same black box warnings as oral JAK inhibitors, it's less likely to cause serious side effects compared to oral medications. Some of the more commonly reported side effects of Opzelura (ruxolitinib) include acne, itching or redness, and symptoms of the common cold.

• Mild-to-moderate eczema that didn't respond well to or can't be treated by other medications
• Vitiligo that appears on both sides of the body (nonsegmental)

Atopic dermatitis:

• Runny nose, sore throat (3%)
• Bronchitis (1%)
• Ear infection (1%)
• Hives (1%)
• Diarrhea (1%)
• Redness and swelling around hair pores (1%)
• Swelling of the tonsils (1%)

Nonsegmental vitiligo:

• Acne on application site (6%)
• Itching on application site (5%)
• Runny nose, sore throat (4%)
• Headache (4%)
• Urinary tract infection (2%)
• Redness on application site (2%)

• Serious infections
• Possible higher risk of death
• Possible risk of cancer
• Possible risk of heart attack, stroke, and other blood clots
• Low blood cell counts
• High cholesterol